Finding should enhance treatments that stop immune system attacks
Image of human intestine from patient with inflammatory disease
Dr Mark Travis and his team at the Manchester Collaborative Centre for Inflammation Research have been studying an important cell that prevents harmful immune responses. Their research detailing how regulatory T cells can cure inflammatory disease has been published in the journal Immunity.
T cells are important in fighting infection as they're mostly designed to act against foreign invaders to the body such as pathogens. But there are some T-cells that react and attack our own tissues, resulting in autoimmune diseases, such as type I diabetes and rheumatoid arthritis. Regulatory T cells are crucial cells in stopping these harmful T cells from causing disease, and are therefore being used as potential therapies to treat autoimmune diseases.
The Manchester researchers have identified new and crucial molecules which allow regulatory T cells to function and cure active inflammation during disease.
Dr Travis explains the importance of their work: "Regulatory T cells are already being used in clinical trials where the cells are taken from the patient, multiplied and then given back to the patient to suppress their illness. By understanding the mechanisms behind how regulatory T cells work, we could improve on these therapies, which can be potentially useful in conditions ranging from type 1 diabetes to multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.
"This knowledge is vitally important when trying to make regulatory T-cells for therapy. By knowing the importance of this pathway, we can now work to improve the suppressive nature of regulatory T cells to make them more effective as treatments for disease."
He continues: "It's fascinating that getting rid of just one molecule can have such an impact on the body's ability to fight disease. Our research is all about how the molecules interlink and react to each other, and in certain situations targeting just one molecule can boost or inhibit a response."
For this paper the Manchester researchers demonstrated that the same molecules are expressed in humans as well as animal models. The next step will be to look at how the mechanism works in humans during disease, for which they plan to target inflammatory bowel disease.
Dr John Worthington, a Wellcome Trust Stepping Stones Fellow, worked alongside Dr Travis on the paper: "We're hopeful this research will have a real impact on treatment therapies that use regulatory T cells, either by boosting their function by targeting this pathway or by cherry picking the very best regulatory cells to prevent autoimmunity. Understanding how these cells operate in such detail can only lead to more effective ways to fight a whole range of inflammatory conditions."
Notes for editors
The paper: "Integrin αvβ8-mediated TGFβ activation by effector regulatory T cells is essential for suppression of T cell-mediated inflammation" will be published in the journal Immunity.
The research was funded by the Medical Research Council and the Wellcome Trust.
For more information and interview requests please contact:
Morwenna Grills
The University of Manchester
Mob: +44 (0)7920 087466
MORE FROM Immune System
07/11/2019 Immune System
New vaccine strategy boosts T-cell therapy
B cells off the rails early in lupus
Treatment approved for patients with acute graft-versus-host disease
How common gut bacteria trigger a lethal autoimmune disease
Imaging Tests Help Reveal Heart Risks in Patients with Psoriatic Disease
05/28/2019 Vaccines & Immunizations
Vaccine one step closer for one of the world's biggest killers
Biotech startup uses nanoparticles to induce immune tolerance
05/20/2019 Vaccines & Immunizations NEW SINGLE VACCINATION APPROACH TO KILLER DISEASES
Inactivated polio vaccine now introduced worldwide
Biomarker for chronic fatigue syndrome identified
Researchers discover a new molecular mechanism in cytomegalovirus to subvert immune response during viral infection
Breakthrough Study of Cell Signaling Holds Promise for Immune Research and Beyond
Immunological scarring from coeliac disease
Scientists Discover How Neuroactive Steroids Dampen Inflammatory Signaling in Immune System and Brain
In myasthenia gravis, surgery to remove the thymus gland provides clinical benefits even five years later
Helmholtz scientists identify the causes of cortisone induced side effects